Investment Analysts’ Weekly Ratings Updates for Veru (VERU)

A number of firms have modified their ratings and price targets on shares of Veru (NASDAQ: VERU) recently:

• 10/16/2026 – Veru was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/14/2026 – Veru had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 10/6/2026 – Veru is now covered by Westpark Capital. They set a “buy” rating on the stock.
• 10/2/2026 – Veru was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/27/2026 – Veru was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/19/2026 – Veru was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/16/2026 – Veru was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/2/2026 – Veru was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.